San Diego Life Sciences Roundup: Illumina, Sequenom, Acutus, & More
(Page 2 of 2)
general corporate purposes, including R&D expenses, capital expenditures, working capital, and general administrative expenses.
—Vertex Pharmaceuticals (NASDAQ: VRTX) plans to run a series of small clinical trials intended to test different combinations of antiviral medicines against hepatitis C. The Cambridge, MA-based company, which has significant operations in San Diego, says the series of trials it’s running with South San Francisco-based Alios Biopharma will help to identify a combination of drugs that can raise the hepatitis C cure rate while reducing the side effects for millions of patients.
—The non-profit West Wireless Health Institute said it began a year-long study of Sense4Baby, the San Diego institute’s first experimental wireless medical device for monitoring fetal vital signs, in Yucatan, Mexico, under a joint research agreement with the Carlos Slim Health. By providing wireless remote monitoring by clinicians and community health workers, the institutes are demonstrating their mutual goal of extending the reach of patient care anywhere.
—San Diego’s La Jolla Pharmaceutical, which trades on the over-the-counter market, acquired rights to an experimental drug from privately held Solana Therapeutics that appears to inhibit a specific immune response implicated in cancer and chronic organ failure. La Jolla Pharmaceutical also named former Solana Therapeutics CEO George Tidmarsh as CEO.
—London’s Advent Venture Partners said it has invested $2.2 million from its dedicated life sciences fund in Acutus Medical, a medical technology company based in San Diego and Zurich that is developing an electrophysiological mapping system to help treat patients with irregular heartbeats. Advent said its investment is part of a $5.4 million Series A Round that was previously disclosed. Index Ventures and company founders also participated.